Gabather AB presents preclinical and clinical data of the Lead Drug Candidate, GT-002, at the American Society for Neurosciences (AfN) meeting in Chicago.

Gabather AB announces that today the company has a poster presentation summarizing the preclinical and clinical data of GT-002 at the AfN meeting in Chicago. The meeting is the biggest scientific meeting within Neurosciences with more than 26 500 international participants. The presentation includes the preclinical data accumulated during the last years as well as clinical data from the previous phase Ia study in healthy volunteers that was finalized in the second quarter of 2019 (Single Ascending Dose study, SAD).

"We are both proud and happy to present our data and research at this large neuroscience meeting and to be able to discuss the results and our research program with international collaborators from  both academic and industrial backgrounds. This gives us new possibilities to make new contacts and  meet new potential international partners within both the academic and industrial sectors. It is also rewarding to present and discuss the scientific background on which the GT-002 project is based as we move on to the coming phase Ia/IIb studies (Multiple Ascending Dose, MAD study)", says Michael-Robin Witt, CEO Gabather.

Gabather AB

Michael Robin Witt, CEO

E-mail: [email protected]

About Gabather AB (publ)

Gabather was founded in 2014, based on 10 years research at Lund University and Research Institute of Biological Psychiatry in Roskilde, to develop new drug candidates for the treatment of CNS diseases. Gabather was founded by Forskarpatent I Syd AB and inventors Olov Sterner and Mogens Nielsen, with the purpose of commercializing Sterner's and Nielsen's inventions. Sterner has worked with medicinal chemistry for 40 years, and Nielsen has worked in neuroscience for 45 years.

Gabather is listed on Nasdaq First North Growth Market and Certified Advisor is Erik Penser Bank  and are reachable via +46 (0) 8-463 83 00 or [email protected].

Forward-looking statement

This press release may contain forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, similar to research and development work in the biotech field, associated with risk and uncertainty. In light of this, actual outcomes may differ substantially from what is described in this press release. Gabather is listed on First North Growth Market and Eric Penser Bank is Certified Advisor.

Om Gabather

Gabathers affärsidé är att utveckla nya läkemedel för att behandla sjukdomar inom det centrala nervsystemet med nya verkansvägar, större träffsäkerhet och mindre biverkningar.



Kurs ()
Förändring ()
Marknad Nasdaq First North Growth Market Kortnamn GABA ISIN-kod SE0010869552 Certified Adviser Corpura Fondkommission AB


Michael-Robin Witt VD [email protected] 073-687 28 39